VTA1

Across TCGA pan-cancer cohorts, VTA1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated VTA1 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher VTA1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated VTA1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where VTA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.639	0.426	.023	7	view →
LSCC	OS	Quartile	III,IV	0.493	1.000	.026	4	view →
HNSC	DFS	Median	II,III,IV	0.861	0.703	.018	1	view →
GBM	DFS	Tertile	All	0.832	0.705	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

VTA1–PDAC (OS)

Open the PDAC breakdown →